v-Raf Murine Sarcoma Viral Oncogene Mutation Status in Serous Borderline Ovarian Tumors and the Effect on Clinical Behavior
v-Raf Murine Sarcoma Viral Oncogene Mutation Status in Serous Borderline Ovarian Tumors and the Effect on Clinical Behavior
复制标题
DOI：
10.1111/igc.0b013e3181a83119
复制
发表时间：
2009-12-01
影响因子：
4.8
通讯作者：
Dorsman, Josephine C.
中科院分区：
文献类型：
--
作者：
Verbruggen, Marjolijn B.;Sieben, Nathalie L. G.;Dorsman, Josephine C.
目的：确定 30 例卵巢浆液性交界性肿瘤 (SBT) 和伴随植入物中激活 v-raf 鼠肉瘤病毒癌基因 (BRAF) 突变的发生率，并将 BRAF 突变状态与这些肿瘤的临床行为联系起来。方法和结果：分析了 30 名患者的浆液性交界性肿瘤和非侵入性植入物中是否存在 BRAF V599E 突变，突变状态与 70 个月的卵巢癌相关临床随访。可以在 27 个 SBT 中评估突变状态。 11 人 (41%) 显示了 BRAF 模拟。 5 名双侧 SBT 患者中有 4 名 (80%) 双侧卵巢均出现 BRAF 突变。在对 BRAF 进行分析的 8 个植入物中，有 2 个 (25%) 与其原发肿瘤一起发生突变。 v-Raf 鼠肉瘤病毒癌基因突变阳性 SBT 往往表现出较低的国际妇产科联合会分期和较高的肿瘤体积，并且较少出现非整倍体。 70个月的随访表明这些组之间没有显着的无复发生存差异。结论：v-Raf鼠肉瘤病毒癌基因突变在卵巢SBT中很常见，与双侧肿瘤密切相关，并且也在植入物中发现。应研究更多的肿瘤来评估 SBT 中 BRAF 突变状态的临床重要性。
Aims: To determine the incidence of activating v-raf murine sarcoma viral oncogene (BRAF) mutations in 30 serous borderline tumors (SBTs) of the ovary and the accompanying implants and to link BRAF mutation status to the clinical behavior of these tumors.Methods and Results: Serous borderline tumors and noninvasive implants of 30 patients were analyzed for the presence of the BRAF V599E mutation, and mutation status was correlated to 70 months of clinical follow-up. Mutation status could be assessed in 27 SBTs. Eleven (41%) showed a BRAF mulation. Four (80%) of 5 patients with bilateral SBT showed a BRAF mutation in both ovaries. From the 8 implants that were analyzed for BRAF, 2 (25%) were mutated together with their primary tumor. v-Raf murine sarcoma viral oncogene mutation positive SBTs tend to present with a lower International Federation of Gynecology and Obstetrics stage and a higher tumor volume and are less frequently aneuploid. Seventy months' follow-up indicated no significant recurrence-free survival difference between these groups.Conclusions: v-Raf murine sarcoma viral oncogene mutations are common in ovarian SBT, are strongly associated with bilateral tumors, and are also found in implants. A larger number of tumors should be investigated to assess clinical importance of BRAF mutation status in SBTs.